Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 37.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 610,681 shares of the company's stock after selling 367,171 shares during the quarter. Dimensional Fund Advisors LP owned about 0.99% of Replimune Group worth $5,495,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in REPL. Acadian Asset Management LLC acquired a new position in Replimune Group in the 1st quarter valued at about $927,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Replimune Group during the first quarter worth approximately $1,088,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock worth $53,505,000 after purchasing an additional 699,679 shares during the period. Fisher Asset Management LLC grew its position in Replimune Group by 37.7% in the 4th quarter. Fisher Asset Management LLC now owns 77,663 shares of the company's stock valued at $655,000 after buying an additional 21,267 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock valued at $45,000 after buying an additional 4,946 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the company's stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.60% of the company's stock.

Replimune Group Price Performance

Shares of Replimune Group stock traded up $0.04 on Wednesday, hitting $11.78. The company's stock had a trading volume of 342,145 shares, compared to its average volume of 1,114,350. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a fifty day moving average price of $10.58 and a 200-day moving average price of $8.69. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $15.54. The company has a market capitalization of $723.47 million, a P/E ratio of -3.64 and a beta of 1.21.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.10. On average, equities research analysts expect that Replimune Group, Inc. will post -3.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Replimune Group in a research note on Monday, September 16th. Roth Mkm began coverage on Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 24th. Finally, Roth Capital upgraded Replimune Group to a "strong-buy" rating in a research note on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $16.80.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.